- Home
- VLGEA vs RIGL Comparison
VLGEA vs RIGL Comparison
Compare VLGEA & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VLGEA | RIGL |
|---|---|---|
| Founded | 1937 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.5M | 683.2M |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VLGEA | RIGL |
|---|---|---|
| Price | $39.24 | $34.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $43.20 |
| AVG Volume (30 Days) | 40.9K | ★ 258.5K |
| Earning Date | 01-01-0001 | 04-01-2026 |
| Dividend Yield | ★ 2.50% | N/A |
| EPS Growth | N/A | ★ 807.14 |
| EPS | N/A | ★ 5.38 |
| Revenue | ★ $1,612,015,000.00 | $179,278,000.00 |
| Revenue This Year | N/A | $66.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.31 | ★ $6.41 |
| Revenue Growth | 0.46 | ★ 53.38 |
| 52 Week Low | $30.08 | $15.50 |
| 52 Week High | $40.15 | $52.24 |
Technical Indicators
Market Signals| Indicator | VLGEA | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 58.68 | 41.31 |
| Support Level | $36.20 | $33.05 |
| Resistance Level | $39.76 | $43.18 |
| Average True Range (ATR) | 1.34 | 1.43 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 68.60 | 30.81 |
Price Performance
Historical ComparisonAbout VLGEA Village Super Market Inc.
Village Super Market Inc operates a chain of ShopRite supermarkets, a few of which are in northern New Jersey, southern New Jersey, Maryland, and in northeastern Pennsylvania. The company is a member of Wakefern Food Corporation (Wakefern), a retailer-owned food cooperative and owner of the ShopRite name. It consists of one operating segment, the retail sale of food and nonfood products.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.